Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential.
bimekizumab
bispecific agent
dual specific agent
psoriasis
psoriatic arthritis
Journal
Psoriasis (Auckland, N.Z.)
ISSN: 2230-326X
Titre abrégé: Psoriasis (Auckl)
Pays: New Zealand
ID NLM: 101709086
Informations de publication
Date de publication:
2019
2019
Historique:
received:
14
02
2019
accepted:
01
05
2019
entrez:
20
6
2019
pubmed:
20
6
2019
medline:
20
6
2019
Statut:
epublish
Résumé
Plaque psoriasis (PsO) is a chronic inflammatory skin disorder that may be associated with several comorbidities, including arthritis. The increasing knowledge of psoriasis pathogenesis led to the identification of novel targeted therapeutic interventions. Among them, anti-IL-17A and anti-IL-17F antibodies are currently being investigated for the treatment of PsO and/or psoriatic arthritis (PsA). Bimekizumab is one of these agents, capable ofsimultaneously neutralizing both IL-17A and IL-17F cytokines. In this review we included preclinical and clinical data related to this highly promising agent that shows a peculiar molecular structure differing from other bispecific agents.
Identifiants
pubmed: 31214486
doi: 10.2147/PTT.S179283
pii: 179283
pmc: PMC6538010
doi:
Types de publication
Journal Article
Langues
eng
Pagination
29-35Commentaires et corrections
Type : ErratumIn
Déclaration de conflit d'intérêts
Dr Andrea Chiricozzi has been an advisory board member and consultant, and has received fees and speaker’s honoraria or has participated in clinical trials for Abbvie, Biogen, Fresenius Kabi, Leo Pharma, Lilly, Novartis, UCB-Pharma, Sanofi, and Janssen. The other authors, Prof. Dr Clara De Simone, Dr Barbara Fossati, and Professor Ketty Peris report no conflicts of interest in this work.
Références
Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii14-7
pubmed: 15708927
J Immunol. 2008 Aug 15;181(4):2799-805
pubmed: 18684971
J Immunol. 2010 Mar 24;184(9):5263-5270
pubmed: 20335534
J Invest Dermatol. 2011 Mar;131(3):677-87
pubmed: 21085185
Protein Cell. 2011 Jan;2(1):26-40
pubmed: 21337007
J Immunol. 2013 Mar 1;190(5):2252-62
pubmed: 23359500
PLoS One. 2014 Feb 28;9(2):e90284
pubmed: 24587313
Arthritis Res Ther. 2014 Aug 22;16(4):426
pubmed: 25146432
Br J Dermatol. 2016 Jan;174(1):136-45
pubmed: 26189551
Expert Opin Investig Drugs. 2016 Jul;25(7):751-4
pubmed: 27153320
Br J Clin Pharmacol. 2017 May;83(5):991-1001
pubmed: 27859546
Cold Spring Harb Perspect Biol. 2018 Apr 2;10(4):
pubmed: 28620097
Ann Rheum Dis. 2018 Apr;77(4):523-532
pubmed: 29275332
Int J Mol Sci. 2018 Jan 08;19(1):null
pubmed: 29316717
J Am Acad Dermatol. 2018 Aug;79(2):277-286.e10
pubmed: 29609013
Clin Rev Allergy Immunol. 2018 Dec;55(3):379-390
pubmed: 30109481
J Am Acad Dermatol. 2019 Mar 27;:null
pubmed: 30926369